SPRIM PRO and ObvioHealth have announced an expansion of their partnership to provide a fully integrated trial solution.

ViiV's Cabenuva is administered every two months and was offered to HIV patients who achieved viral suppression from daily treatments.

The timing of the exposure during pregnancy made a big difference in the level of risk associated with developing an allergic condition.